It looks like you're accessing our website from North America. We have a dedicated page tailored to your region, offering the most relevant information and services.
If you have an existing eCom account, you can log in to the North American site using your current username and password.
Would you like to visit the North America page?
You can access the page here
If you have any questions, please feel free to contact our support team hytest@hytest.fi
The article describes the development of a novel immunoassay for the quantification of BNP fragments cleaved by neprilysin. The study shows that the concentration of the neprilysin cleaved BNP fragments varies in patients with heart failure and that the ratio of cleaved BNP/total BNP does not correlate with the concentration of total BNP making it an independent parameter. The results obtained in this study indicate that it might be possible to prescreen patients that would benefit from neprilysin inhibition treatment (Entresto™) using the novel immunoassay. The assay could also be used for monitor the efficacy of the treatment.
Copyright © 2025 Hytest Ltd.